Floyd E. Taub, M.D., has spent 30 years studying pathology, immunology, oncology and infectious diseases. He has literally changed the paradigm in several fields:

  • Dr. Taub invented and implemented the first Computerized Image Processing Techniques to measure Gene Expression Levels (Genomics) via Arrays. He did this while at the National Institutes of Health (NCI) in 1999, significantly before the word “Genomics” existed.
  • Dr. Taub modernized PAP screening, the most important cancer screening test in existence. He started, and for 8 years led, the company (DIGENE) that developed the only FDA approved test to determine if a woman has, or is at high risk of developing, cervical cancer. Instead of using subjective morphologic criteria he instituted DNA determination of the presence of oncogenes in the high risk HPV types. This test was first approved for difficult cases and it is now approved a part of routine screening in the U.S.A. Scientific journals have suggested that in areas of the world with limited resources it should be the only screen used. It has been covered extensively by the lay press. In addition to detecting otherwise missed potentially lethal conditions, the test prevents unnecessary surgery in women who do not have a dangerous virus. It has become the "Gold Standard" in protection against cervical cancer.
  • Dr. Taub coined the terms NanoDrugs™ and Adaptive MicroMeds™ has led their development. This includes Phase I/II Clinical Trials, Clinical Outcome Studies and introduction of what is believed to be the most potent and among the safest scientifically documented drugs on the market. By modulating the immune system, Taurox™ and Beta LT ™ effectively reduce fatigue and often other symptoms in patients with neoplastic, infectious and post infectious syndromes including chronic viral hepatitis, Lyme Disease, cold & flu and cancer. Modulation of the expression of genes and cytokines has been documented in vitro and in vivo.
  • He started a non-profit called FindCure.Org (previously Victory Over Cancer and Chronic Conditions.) FindCure has dramatically accelerated the availability these drugs. He designed and participated in the performance and analysis of clinical trials.
  • Dr. Taub has developed drugs, which unlike standard cancer and hepatitis drugs, appear to meet what is commonly called the “Hippocratic Oath”. No prescription medicines and few other over-the-counter (OTC) medicines “do no harm”.
  • For the latest scientific finds on one of these drugs, Taurox™, see Dr. Taub's Presentation at Exeter University Medical School.

Curriculum Vitae

  •  Diagnostics:  Dr. Taub is best known for changing both the concept and “gold standard” of cervical cancer screening. In 1984 he founded Digene, Inc.    Digene is the only company with an FDA approved DNA test to subtype HPV.  Scientific journals have suggested that in resource challenged areas it should be the only screen used. Europeans have proposed that it replace the morphologic PAP smear as the initial screen.  Understanding the importance of oncogenic HPV types led to the vaccine to prevent cervical cancer.
  • Genomics: Dr. Taub invented and implemented the first computerized image processing techniques to measure gene expression levels via array analysis while at the National Institutes of Health (NCI) in 1999.  A miniaturized version of this is still a widely used advanced research tool at present.  It is now being implemented as a clinical tool in leading medical centers. (July, 2008)  
  • Therapeutics: Dr.  Taub has led clinical development of a number of drugs, including the most potent cancer therapy that has been tested in Phase I/II trials and the most potent OTC drug currently available.  He has specialized in oncology and immunotherapeutics.

Historical Review
==========     

2014 Consulting Chief Science Officer for Veramarx In his first two months with Veramarx, Dr. Taub developed and validated a unique novel assay for Lyme Disease with greater than 90% accuracy. It measures earlier steps of immune respone than current methods (which miss 40% of the cases) and thus it detects the disease before other methods.

2010 - Primary ongoing Position Consulting Partner with ClearCreek Partners, LLC.
ClearCreek Partners provides capital solutions for emerging companies. ClearCreek is a financial advisory firm that works with entrepreneurs and CBO's of private companies, first to understand the personal needs and business objectives of each client, and then to access the most appropriate financing sources and strategic partners. Dr. Taub heads the biomedical practice. Dr. Taub also consuls for companies not yet ready for an "A" round.

2009-2011 Consulting Medical Officer for Zetiq, Inc
Zetiq implemented a new histologic stain that differentiates cancer and normal cells. Dr. Taub's suggestion added applications.

2009 Consulting Chief Medical Officer for Eveia Medical
Eveia investigated a new format of immunoassay that achieves a separation step in solution, allowing enhance signal to noise ratio and thus increased clinical sensitivity. Eveia also is implementing home use disposable card assays for anemia and coagulation (coumadin) status. Dr. Taub was the internal sponsor of the close to market anemia tests. He defined an initial indication for the first anemia product that was easier to achieve from both technical and regulatory standpoints.

2008 to 2009, Consulting Chief Medical Officer, OTraces, Inc. 
OTraces has multianalyte screening tests for cancer.  Initial data indicate breast, prostate and lung cancer can be detected with a sensitivity and specificity in excess of 90% -95% by analyzing serum.  Dr. Taub revised the regulatory and clinical trial strategy.

2007 CEO of CytoCore, Inc. (CYOE)
Developer of diagnostic and therapeutic products for genitourinary cancers.

  • Main accomplishments:
    • Revised regulatory strategy eliminating need for additional trials prior to approval of first product.
    • Revised clinical trial strategy, eliminated trials later proven to be failures and added new trials latter proven to be necessary fro success.
    • Added second and third products.
    • Replaced underlying technique to allow a cancer diagnostic product to beat schedule.
    • Defined more easily met and clinically more important value propositions and endpoints for clinical trials. 

2005-Present: Founder & Director of CureImmune Corporation.
CureImmune is a  developer of scientifically proven OTC immune modulating therapies  

  • Main accomplishments:
  • Initiated sales of a product line based on a novel OTC drug (carbo-benzoxy beta alanyl taurine/Taurox™).  This is the most potent OTC drug known.
  • Out licensed to a larger company for up front payments, royalty payments and a commitment to a major marketing campaign. 

1999-Present: Founder of LifeTime Pharmaceuticals Inc.
LifeTime is a clinical-stage pharmaceutical company focused on "fast tracked" small molecules designed to treat life-threatening diseases.

  • Main accomplishments:
  • Conducted Phase I/II clinical trials of Beta LT (beta-alethine)
  • Data presented by McGill at the American Society of Hematology indicated low toxicity, immune stimulation and cancer shrinkage.
  • Early termination of Phase I/II clinical trials at McGill University/JGH due to positive results. These studies supported the mechanism of action of the drug, demonstrated biological activity in people, at low doses, defined a patient population especially suitable for treatment, and most importantly, provided evidence of anti-cancer activity with no detectable toxicity.
  • Ongoing CRADA (Cooperative Research and Development Agreement) with Battelle labs and international collaborators for the further testing and development of pharmaceutical compounds based on the active ingredients in garlic.  One compound with both cancer cytotoxic and host cell immunotherapeutic properties has been identified.
  • Ongoing CRADA (Cooperative Research and Development Agreement) with Battelle labs and international collaborators for the further testing and development of pharmaceutical compounds based on brain derived small peptides that may replace Neupogen and other white blood cell stimulants.

1997-Present: Founder FindCure.Org ( previously Victory Over Cancer and Chronic Conditions). FindCure is a non-profit organization committed to stimulate clinical development of non-toxic agents that can modulate the immune system to better fight cancer, in people and in pets. The Foundation's motto is "Developing and Distributing New Therapies". The focus includes lymphoma, myeloma, brain and colon cancer and other diseases in which immune systems stimulation may help. It provides free therapy to those in need.

1994-2005: Founder and Chairman of Dovetail Technologies Inc. DTI is leading a paradigm shift by identifying and applying drugs 1 thousand to 1 million-fold more potent than conventional drugs. This Nanodrug technology offers ultra high potency, ultra low toxicity and virtually side effect free therapy. It reduces frequency of administration for easier and more effective patient compliance and lower cost. Dovetail engaged in research, development and commercialization of cutting edge, patented, immuno-therapeutic technologies for illnesses including cancer, hepatitis, HIV, allergies, fatigue, flu and the common cold.

Main Accomplishments

  • Brought Lead Drug product to market without major outside capitalization
  • Developed the technology used by LifeTime Pharmaceuticals, Inc

Dovetail's first products, each containing Taurox and other ingredients were labeled for the treatment of fatigue and allergies, cold and flu. It reduced fatigue by optimizing the immune system. These products reached the market six months ahead of plan due to achieving statistically significant effects in patients with cancer, hepatitis and chronic fatigue syndrome very rapidly. Over 90% of patients experience a reduction in fatigue in clinical trials. Symptoms are typically reduced 50-66%. The product is now sold nationwide through a variety of marketing arrangements. Post marketing analysis confirms the commercial preparation has the same activities as seen in the clinical trials. The overwhelming majority of patients respond and it allows some debilitated patients to return to normal activities.

1984 -1990: Founder, CEO, President and V.P. of Research and Development, Digene Diagnostics, Inc. Guided corporate development and technical R&D during the organizations growth from 1 to 50 employees. Digene developed reagents for and clinical methods for using diagnostic DNA techniques.

Main accomplishment: Identified the need for and then conceived, designed, developed, and marketed diagnostic tests to help prevent either under treatment or unnecessary surgical treatment that results from the frequently inaccurate "PAP" smear. Digene's tests distinguish those abnormalities which contain types of papilloma virus (HPV) of the type that cause cancer from identical appearing abnormalities which are not pre-cancerous since they do not contain oncogenic papilloma viruses. Digene still (May 2006) is the only provider of a FDA approved diagnostic for HPV typing. It has been approved as part of routine screening and has become the standard of optimal care.

Additional accomplishments at Digene:

  • Raised over seven (7) million dollars.
  • Negotiated a corporate partnership with Mitsubishi Petrochemical Company, Ltd., to fund R&D and to distribute Digene's products in Japan. This arrangement retained all Digene's technology and product manufacture rights and specified "flowback" for Mitsubishi technology and products in the DNA field.
  • Conceived, wrote, and executed research grants and contracts in excess of $1.3 million under the federal Small Business Innovative Research (SBIR) program. Achieved 100% success rate on Phase II applications and in completion of major project goals.
  • Marketed a line of molecular biology reagents, services, and DNA probe tests. Sixteen DNA probe kits were developed.
  • Designed and outfitted 3 facilities, including a 9,500 sq. ft. R+D facility built to specifications and a 10,000 sq. ft. manufacturing facility.
  • Authored six patent applications and numerous disclosures in DNA probes, molecular biology and diagnostic medicine.
  • Qualified DDI as the first biotechnology company to be admitted to the University of Maryland Technology Advancement Program and subsequently qualified Digene to be a "jump start" (rapid sales growth) company, as evaluated by Washington High Technology.

1982-1984: Head, Pathology Unit, Laboratory of Oral Medicine (Chief: Abner Notkins, M.D.) National Institute of Dental Research, and National Institutes of Health, Bethesda, MD. The unit specialized in the use of human monoclonal antibodies (derived by hybridoma technology and EBV transformation) in pathology and in the study of autoimmunity. Several of these antibodies were evaluated as clinical diagnostic tools for detecting and evaluating cancers. Research and clinical assays of autoimmunity in diabetes were developed.

1981-1982: First Surgical Pathology Fellow at George Washington University (Head, Anatomic Pathology: Steven Silverberg, M.D.). Served as "Attending Pathologist."

1978-1981: Research Associate, National Cancer Institute, Laboratory of Biochemistry (Chiefs: Robert Goldberger, M.D., and Maxine Singer, Ph.D.), Biochemistry of Gene Expression Section (Head: E. Brad Thompson). Studies on the control of glucocorticoid inducible genes. The methods used included recombinant DNA technology, somatic cell hybridizations, enzyme purification, antibody production, and solution and filter hybridization of nucleic acids. This work included differential screening of a rat liver cDNA library to directly identify clones containing glucocorticoid-induced or -repressed RNA sequences.

Developed a unique system using computerized image processing, enhancement, and quantification to evaluate gene expression (Genomics) via solution-solid phase hybridization to each member of a cDNA library. This technology allowed detailed study of gene regulation and isolation of specific recombinant clones. This new system is the nucleic acid counterpart of comparative two-dimensional protein gel electrophoresis.

1976-1978: Autopsy Supervisor, University of Colorado Medical Center. Designed the program and was responsible for supervising the autopsy-related work of up to 12 physicians. Favorable evaluation led to the program's continuation after his tenure at UCMC ended.

Research with Paul Nakane, Ph.D., Pathology Department, University of Colorado Medical Center. Differentiation of pituitary cells following endocrine manipulation in vivo was studied. Techniques used included multiple peroxidase-labeled anti-hormone antibodies and flow microfluorometry.

1974-1976: Research with Terry Johnson, Ph.D., Department of Microbiology, Northwestern University Medical School. (Dr. Johnson is now Professor/Director of the Division of Biology, Kansas State University.) A model system for pediatric brain damage in the genetic disease phenylketonuria (PKU) was examined. Nucleic acid and protein biochemistry defined the molecular site of inhibition of protein synthesis in immature rat brain following phenylalanine overloading. Based on this work, a new therapeutic approach was devised. This approach was effective in an animal model of PKU.

1971: National Science Foundation Research Participation Program Grantee for work with Aryeh Routtenberg, Ph.D., at Northwestern University Psychology Department. A novel method for determination and documentation of functional relationships between structurally diverse CNS regions was devised.

1968-1969: Research and study under Rulon Rawson, M.D., Vice President and Dean, New Jersey College of Medicine and Dentistry. In vivo studies of induction of red blood cell production by erythropoietin (epo) following radiation injury were performed. This work led to a Special Army Science Award. Epo class drugs have a market of over $5 billion and for many years been the best selling biotechnology drugs. The are used to treat fatigue. However unlike the drugs Dr. Taub has recently developed their use is limited to those with anemia.

Representative Invited Presentations:

  • Cambridge Healthtech Institute, Baltimore, MD
  • Cambridge Healthtech Institute, Tyson's Corner, VA
  • A-T Children's Project, Longwood Gardens, PA
  • Northwestern University, Evanston, IL
  • Biogen, Geneva, Switzerland
  • University of Chicago
  • University of California-Los Angeles
  • George Washington University, Washington, DC
  • Bethesda Research Laboratories, Bethesda, MD
  • Diabetes Telethon
  • Physicians Radio Network
  • XI Congreso de Investigacion Cientifica, San Juan, Puerto Rico
  • Society for Industrial Microbiology annual meeting, Baltimore, MD
  • Dental Research Programs Advisory Committee, NIH, Bethesda, MD
  • Baxter Healthcare Corporation, Deerfield, IL
  • Montana Society of Pathologists, Great Falls, MT
  • University of Texas Medical Branch, Galveston, TX
  • Congressional subcommittee hearing on Technology Transfer, Washington, DC
  • Portfolio Management for the Biotech Industry, San Diego, CA

Societies (not all current):

  • Academy for the Advancement of Medicine
  • American Academy of Anti-Aging Medicine
  • American Association for the Advancement of Science
  • American Association for Clinical Chemistry
  • American Society of Hematology
  • American Society for Microbiology, American Society of Clinical Pathologists
  • Foundation for Advanced Education in the Sciences
  • International Academy of Pathology
  • New York Academy of Sciences
  • Sigma Xi
  • Society for Biological Therapy
  • Honored Memberť Strathmore's Who's Who 2000-2001 (Millennium Edition)
  • The Official ABMS Directory of Certified Medical Specialists.

Historic Review of Medical Training

1970-1976

Entered Northwestern University's Honor Program in Medical Education directly from high school.  1974, B.S.  1976, M.D.

1975

Commissioned Jr. Assistant Surgeon, United States Public Health Service.

1976-1978

Anatomic pathology internship and residency, University of Colorado Medical Center.  Subspecialty: endocrine pathology. Training included ultrastructural, immunohistochemical, surgical, and autopsy pathology.  Autopsy supervisor, January to June, 1978.

1980

Promoted to Full Surgeon, United States Public Health Service.

1981-1982

Surgical Pathology Fellow, George Washington University.

1982

Diplomat of the American Board of Pathology.

Current licenses to practice medicine in Maryland and California.
More than 50 publications in scientific literature. Inventor or co-inventor on seven biomedical patents/applications.

Publications

Publications

Most Recent Major Presentation on Taurox

Fatigue Reduction and Quality of Life Enhancement Following Therapy with Taurox. (Presentation at Exeter University (UK) December 2006) Floyd E. Taub, M.D., Char Tara Albert, Lesley Crowder, Suzin Mayerson Wright, Ph.D.

Publications (Papers):

  1. Routenberg A, Taub FE.  Hippocampus and superior colliculus: congruent EEG activity demonstrated by a simple measure.  Behav. Biol., 1973; 8: 80.
  2. Taub F and Johnson TJ.  The mechanism of polyribosome disaggregation in brain tissue by phenylalanine.  Biochem. J., 1975; 151: 173-180.
  3. DeLeo JM, Taub F, Thompson B.  Computer analysis of autoradiographic images of recombinant DNA colonies. Division of Computer Research and Technology Annual Report, 1981; 2:42-43.
  4. Taub FE and Thompson EB.  An improved method for preparing large arrays of bacterial colonies containing plasmids for hybridization:  in situ purification and stable binding of DNA on paper filters.  Anal. Biochem., 1982; 126: 222-230.
  5. Taub FE, DeLeo JM and Thompson EB.  Sequential comparative hybridiza­tions analyzed by computerized image processing can identify and quantitate regulated RNAs.  DNA, 1983; 2: 309-327.
  6. DeLeo JM, Taub F, Thompson B. Computer analysis of autoradiographic images of recombinant DNA colonies. Division of Computer Research and Technology Annual Report, 1983; 2:44-45.
  7. Taub FE. Class II antigen expression in autoimmune disease. Lancet, 1984; 84:561.
  8. Ginsberg-Fellner F, ME Witt, B Fedun, F Taub, MJ Dobersen, RC McEvoy, LZ Cooper, AL Notkins, P Rubinstein. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Review of Infectious Diseases, 1985; 7 (Suppl. 1):S170-S176.
  9. Ginsberg-Fellner F, ME Witt, S Yagihashi, MJ Dobersen, F Taub, B Fedun, RC McEvoy, SH Roman, TF Davies, LZ Cooper, P Rubinstein, AL Notkins. Congenital rubella syndrome as a model for type I (insulin-dependent) diabetes mellitus: increased prevalence of islet cell antibodies. Diabetologia, 1984; 27:87-89.
  10. Ginsberg-Fellner F, ME Witt, S Yagihashi, MJ Dobersen, F Taub, B Fedun, RC McEvoy, SH Roman, TF Davies, LZ Cooper, P Rubinstein, AL Notkins. Congenital rubella syndrome as a model for type I (insulin-dependent) diabetes mellitus: increased prevalence of islet cell antibodies. Diabetologia, 1984; 27:87-89.
  11. Sutherland DER, R Sibley, X-Z Xu, A Michael, S Srikanta, F Taub, J Najarian, FC Goetz (intro. by JH Oppenheimer). Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes. Transactions of the Association of American Physicians, 1984; 97:80-87.
  12. Garzelli C; Taub FE; Scharff JE; Prabhakar BS, Ginsberg-Fellner F; Notkins AL.  Epstein-Barr virus-transformed lymphocytes produce monoclonal autoantibodies that react with antigens in multiple organs.  J Virol 1984; 52: 722-5.
  13. Taub, FE, Satoh, J, Garzelli, C, Essani, K and Notkins, AL.  Human monoclonal autoantibodies reactive with multiple organs.  Human Hybridomas and Monoclonal Antibodies (eds. E.G. Engleman, et al.) Plenum Publishing Corporation, New York, 1985.
  14. Eskinazi DP, J Satoh, CJ Wheeler, ET Harrison Jr., FE Taub. Detection of antibodies reacting with live rat insulinoma cells in the serum of patients with insulin-dependent diabetes mellitus (IDDM) by an 125I-protein A microassay.  Immunology Letters, 1985; 10:353-354.
  15. Garzelli C, FE Taub, MC Jenkins, DW Drell, F Ginsberg-Fellner, AL Notkins. Human monoclonal autoantibodies that react with both pancreatic islets and thyroid. Journal of Clinical Investigation, 1986; 77:1627-1631.
  16. Taub FE. DNA diagnostic techniques in microbiology. SIM News, 1986; 36:6-7.
  17. Hakim FT, AD Steinberg, P Smathers, KS Brown, F Taub, JJ Oppenheim. Hereditary joint disorder in progressive ankylosis (ank/ank) mice: III. Involvement of the immune system. Doctoral dissertation, University of Maryland, 1986.
  18. Taub FE, SL Grillo, CM Bruns, N Moore, ME Mosher. The use of DNA probes to diagnose viral infections. Developments in Industrial Microbiology, 1988; 29 (Journal of Industrial Microbiology, Suppl. No. 3):119-129.
  19. Taub F. In situ hybridization in surgical pathology. Advances in Surgical Pathology lecture at George Washington University, Washington, DC. May 7, 1988.
  20. McClintock JT, Thaker SR, Mosher M, Jones D, Forman M, Charache P, Wright K, Keiser J, Taub FE.  Comparison of in situ hybridization and monoclonal antibodies for early detection of cytomegalovirus in cell culture.  J Clin Microbiol, 1989; 27: 1554-9.
  21. Higgs TW, Moore NJ, Badawi DY and Taub FE.  Type-specific HPV detection in formalin-fixed, paraffin-embedded tissue sections using non-radioactive DNA probes.  Laboratory Investigation, 1990; 63: 557-567.
  22. Schoone GJ, van Eys GJ, Ligthart GS, Taub FE, Zaal J, Mebrahtu Y, Laywer P.  Detection and identification of Leishmania parasites by in situ hybridization with total and recombinant DNA probes.  Exp Parasitol, 1991; 73: 345-53.
  23. McClintock JT, Mosher M, Thaker SR, Wacker WK, Jones D, Forman M, Adler SP, Charache P, Taub FE.  Culture confirmation of cytomegalovirus and herpes simplex virus by direct enzyme-labeled DNA probes and in situ hybridization.  J Virol Methods, 1991; 35: 81-91.
  24. McCarthy M, Resnick L, Taub F, Stewart RV, Dix RD.  Infection of human neural cell aggregate cultures with a clinical isolate of cytomegalovirus.  J Neuropathol Exp Neurol, 1991; 50: 441-50.
  25. McClintock JT, Chan IJ, Thaker SR, Katial A, Taub FE, Aotaki-Keen AE, Hjelmeland LM.   Detection of c-sis proto-oncogene transcripts by direct enzyme-labeled cDNA probes and in situ hybridization.  In Vitro Cell Dev Biol., 1992; 28: 102-8.
  26. McClintock JT, I-J Chan, SR Thaker, A Katial, FE Taub, AE Aotaki-Keen, LM Hjelmeland. The detection of RNA transcripts by non-radioactive in situ hybridization. In preparation.
  27. McClintock JT; Chan IJ; Taub FE; Friedman-Kien AE, Resnick L.  Rapid detection of Epstein-Barr virus DNA in clinical samples of oral hairy leukoplakia with HRP-labeled DNA probes and in situ hybridization.  J Virol Methods, 33, 155-64 (1991.)
  28. Badawi DY, L Etienne, TW Higgs, NJ Moore, FE Taub. Comparison study of non-radioactive probes for the rapid detection of HPV in histological sections. In preparation.
  29. Lazar JG, Taub FE, Kessler C. A highly sensitive method for detecting peroxidase in situ hybridization or immunohistochemical assays. Nonradioactive Labeling and Detection of Biomolecules Berlin: Springer-Verlag; 1992: 135-142.
  30. Dunn T, Wormsley S, Taub FE, and Pontzer CH. Increased T cell cytotoxicity by Beta LTTM-induced upregulation of TNF-alpha. International Journal of Immunopharmacology. 2000: 22, 213-227.

Publications (Abstracts):

  1. Sutherland DER, R Sibley, P Chinn, A Michael, S Srikanta, F Taub, J Najarian, FC Goetz (intr. by JH Oppenheimer). Twin-to-twin pancreas transplantation (TX): reversal and reenactment of the pathogenesis of type I diabetes. Clinical Research, 1984; 32:561A.
  2. Taub FE, J Scharff. Assay of islet cell antibodies (ICA), a more sensitive method. Diabetes, 1984; 33 (Suppl. 1):63A.
  3. Yoon JW, JS Scharff, CJ Bachurski, TH Lee, FE Taub. Antibody to islet cell antigens from patients with Vacor induced insulin-dependent diabetes mellitus. Diabetes, 1984; 33 (Suppl. 1):161A.
  4. Katial A, K Roshto, T Higgs, F Taub. Peroxidase labeled nucleic acid probes. Poster presented to the American Society of Biological Chemists, Washington, DC, 1986.
  5. Taub F, H Rutherford. Processing images of radioautographs to analyze nucleic acid hybridizations: a computerized method to study multiple gene expression.  Poster presented to the American Society of Biolgoical Chemists, Washington, DC 1986.
  6. Katial A, K Roshto, E Cantin, F Taub. Detection of herpes virus using peroxidase labeled nucleic acid probes. Poster presented at the 1st Annual ASM Conference on Biotechnology, Washington, DC, 1986.
  7. Roshto K, T Higgs, A Shaikh, J Saba, F Taub. Background reduction in filter hybridizations. The use of direct nucleic acid horseradish peroxidase conjugates. Poster presented to the American Society of Biological Chemists, 1987.
  8. Grillo S, M Mosher, P Charles, S Henry, F Taub. DNA/DNA in situ hybridization with enzyme linked probes.  Poster presented to the American Society of Biological Chemists, 1987.
  9. Grillo SL, CM Bruns, ME Mosher, FE Taub. The use of direct DNA-peroxidase conjugates for rapid, non-radioactive detection of HPV sequences by in situ hybridization. Poster presented at the 6th International Papillomavirus Workshop, Washington, DC, 1987. Published in Abstracts of Papers Presented at the Sixth International Papillomavirus Workshop, p.105.
  10. Mosher ME, SL Grillo, N Moore, A Maters, R Ambinder, FE Taub. Rapid detection of herpesviruses by in situ hybridization with enzyme-linked probes. Poster presented at the 12th International Herpesvirus Workshop, Philadelphia, PA, 1987.
  11. Mosher ME, SL Grillo, N Moore, A Maters, M Forman, R Ambinder, FE Taub. Rapid detection of virus-infected cells by in situ hybridization using DNA probes directly linked to active enzymes.  Poster presented at Gene Probe Technology II: 1987 American Association for Clinical Chemistry San Diego Conference.
  12. Mosher M, A Maters, D Jones, M Forman, S Grillo, F Taub. Rapid detection of cytomegalovirus-infected cells by in situ hybridization with enzyme-linked DNA probes. Abstracts of the Annual Meeting of the American Society for Microbiology, 1988, p.320.
  13. Bruns CM, C Cardozo, CR Ceccarelli, L Corey, JM Douglas, SL Grillo, A Langenberg, J Saba, FE Taub. Rapid in situ hybridization to HPV DNA sequences in cervical smears using direct enzyme-labeled DNA probes. Poster presented at the 7th International Papillomavirus Workshop, Sophia Antipolis, France, 1988. Published in Seventh International Papillomavirus Workshop, p.30.
  14. Taub, F. In situ hybridization in surgical pathology. Talk given at George Washington University, Washington, D.C. on May 7, 1988, as part of the series, "Advances in Surgical Pathology."
  15. Higgs T, N Moore, G Gamerman, C Bruns, D Badawi, F Taub. Highly sensitive, rapid, and specific detection of HPV types 6/11 and 16/18 in formalin-fixed paraffin-embedded sections using directly conjugated HRP-labeled DNA probes.  Poster presented at the 8th International Papillomavirus Workshop, Taos, NM, 1989. Published in Journal of Cellular Biochemistry, Suppl.13C, 1989, p.187.
  16. Bruns CM, CR Ceccarelli, J Summerville, T Higgs, FE Taub. Type-specific HPV detection in Pap smears by in situ hybridization with enzyme-DNA conjugates. Poster presented at the 8th International Papillomavirus Workshop, Taos, NM, 1989. Published in Journal of Cellular Biochemistry, Suppl.13C, 1989, p.182.
  17. McClintock JT, A Friedman-Kien, F Taub. Direct detection of Epstein-Barr virus in tongue tissue smears from individuals with suspected hairy leukoplakia.  Poster presented to the American Society for Microbiology, New Orleans, LA, 1989. Published in Abstracts of the 89th Annual Meeting of the American Society for Microbiology 1989, p.373.
  18. Wacker WK, JT McClintock, S Strohofer, S Kahn, RP Baughman, FE Taub. Direct detection of cytomegalovirus in bronchoalveolar lavages using HRP-labeled DNA probes and in situ hybridization.  Poster presented to the American Society for Microbiology, New Orleans, LA, 1989. Published in Abstracts of the 89th Annual Meeting of the American Society for Microbiology 1989, p.373.
  19. Badawi D, M Garcia, T Higgs, C King, S Yang, F Taub. Direct-labeled DNA probes for rapid viral diagnosis. Poster presented to the Society for Pediatric Pathology, Aspen, CO, 1989.
  20. King PC, WK Wacker, RP Robinson, J Colandrea, R Robinson, FE Taub. Direct detection of CMV in bronchoalveolar lavage specimens using in situ hybridization. Poster presented to the Pulmonary Pathology conference sponsored by the Washington Hospital Center, Washington, DC, 1989.
  21. King C, W Wacker, R Baughman, J Colandrea, R Robinson, B Weinstein, F Taub. CMV detection in cytologic and histologic specimens, using direct-labeled DNA probes and in situ hybridization. Poster presented at The International Academy of Pathology, Boston, MA, 1990. Published in Modern Pathology 3:52A, 1990.
  22. King C, W Wacker, R Baughman, J Colandrea, R Robinson, B Weinstein, F Taub. CMV detection in cytologic and histologic specimens, using direct-labeled DNA probes and in situ hybridization. Poster presented at The International Academy of Pathology, Boston, MA, 1990. Published in Modern Pathology 3:52A, 1990.
  23. Taub F, C King, T Higgs. Viral identification in situ with direct-labeled DNA probes. Poster presented at the UCLA symposium "Animal Models of Human Viral Diseases: Relevance to Developmental Therapeutics," Keystone, CO, 1990.
  24. Taub F, S Thaker, H Salim, M Wesoloski, D Badawi. "Single copy detection" of HPV16 in SiHa cells with direct HRP-DNA probes. Poster presented at Papillomavirus Workshop 1990, Heidelberg, Germany, 1990.
  25. Taub F, JS Park, D Badawi, K Shah. DNA-HRP probes reveal different morphological patterns of HPV distribution in benign and malignant neoplastic lesions. Poster presented at Papillomavirus Workshop 1990, Heidelberg, Germany, 1990.
  26. Miller W, Caplan S, Shustik C, McQuillan A, Sicilia F, Batist G, Mayerson S, Taub F. Toxicity and Biological Effects of Beta-alethine - Report of the First Phase I/II Study. Poster presented at VII International  Multiple Myeloma Workshop 1999, Stockholm, Sweden 1999.

Publications concerning Beta-alethine:

  1. Taub, F. Beta-alethine (Beta LT): A Low Molecular Weight Cytokine Inducer with Anti-Cancer Properties and Low Toxicity in Mice and Man? Review of Data to Date. Poster presented at Cancer Immunosurveillance 1999 - Cancer Research Institute, New York, New York 1999.
  2. Taub F, Mayerson S, McQuillan A, Caplan S, Shustik C, Miller W. Phase I/II Evaluation of Beta LT as an antilymphoma agent and enhancer of DTH in lymphoma patients. Poster presented at The International Conference on Molecular Targets and Cancer Therapeutics, Washington, D.C. 1999.
  3. Miller WH, Caplan S, Shustik C, McQuillan A, Sicilia F, Mayerson S, Taub F. Beta-alethine Immunomodulation in Follicular B Cell Lymphoma and Multiple Myeloma: Initial Phase I/II Results. Submitted. Blood Supplement (Part II), November 15, 1999.
  4. W.H. Miller, Jr., S. Caplan, C., Shustik, A. McQuillan, F. Sicilia, S. Mayerson and F. Taub. Beta-alethine: TNF alpha, Antitumor Effects and Delayed Type Hypersensitivity in Follicular B-Cell Lymphoma. Oral presentation at the ISH 2000 (28th International Congress) Toronto, Ontario, August 2000.
  5. F. Taub. Review of Beta LT immunomodulation in lab studies and patients with follicular B cell lymphoma: Initial phase I/II results.  Presented at the Comprehensive Cancer Care 2000, Arlington, VA, June 2000.
  6. F. Taub, K. Manos, S. Mayerson. A review of animal models and human clinical trial data supportive of beta-alethine (BT) immune therapy for minimal residual disease (MRD). Presented at the 15th Annual Scientific Meeting of the Society for Biological Therapy, Seattle, WA October 2000.
  7. W.H. Miller, Jr., S. Caplan, C., Shustik, A. McQuillan, F. Sicilia, S. Mayerson and F. Taub. T cells exhibit increased TNF alpha and delayed type hypersensitivity responses are restored in patients with B cell malignancies following administration of beta-alethine. Presented at the American Association for Cancer Research, 11th NCI-EORTC-AACR Symposium Amsterdam, The Netherlands, November 2000.
  8. C.H. Pontzer and F. Taub. Reducing toxicity of recombinant biomolecules through engineering. Presented at the Cambridge Healthtech Institute Recombinant Therapeutics: Antibodies and Biomolecules Conference, Baltimore, MD, June 2001.

Patents:

  1. Taub F. Assay for Nucleic Acid Sequences, Particularly Genetic Lesions, Using Interactive Labels.
  2. Taub F. Bifunctional DNA-Protein Conjugating Agent.
  3. Taub F, Higgs TW, Roshto K. Macromolecular Conjugate.
  4. Higgs TW, Taub F. A Highly Sensitive Method for Detecting Peroxidase.
  5. Taub FE, Lazar J. Macromolecular Conjugate Made by  (confidential).

Scientific Presentations, Conferences and Public Relations in 2003 & 2004 for Taurox

  • Fatigue Reduction and Quality of Life Enhancement Following Therapy with Taurox. (Presentation at Exeter University (UK) December 2006) Floyd E. Taub, M.D., Char Tara Albert, Lesley Crowder, Suzin Mayerson Wright, Ph.D.
  • 11th Annual Meeting of the Society for Orthomolecular Health-Medicine (OHM) in San Francisco, California, February 24-27, 2005, Fatigue Reduction Due to Changing Cytokine Patterns.  Immunostimulation by COBAT (Taurox SB) in Patients with Lyme Diseaseť
  • KFNX News Talk Radio, August 8th, 2004, 8:00 a.m. PST
    Floyd Taub, M.D. was interviewed by Dr. Warren Levin, Host of the show, "Third Opinion"
  • Familynet Television Interview June 17 and 25, 2004
    BioInnovations produces a daily television show for the Familynet cable network, which broadcasts to over 30-million viewers mainly in the Midwest and South, hosted by Dr. Richard Becker and his wife Cindy. Allergy Research Group, one of Dovetail's distributors introduced the Beckers to Dr. Floyd Taub, Dovetail Technology's Chairman and Chief Medical Officer.  Dr. Taub participated in two 30-minute television shows on June 17, 2004 discussing Taurox research. One aired live on Familynet Television that day, the second program aired on June 25, 2004. Familynet is a television service dedicated to health and family matters and provides holistic medical information that is generally not available to its audience other than through Dr. Becker.
  • Health Sciences Institute (HIS) Newsletter, May 2004 Issue
    HIS published an article entitled 'What the Goldilocks effect'ť can do for fatigue and your immune systemť, covering Taurox research and products.

Sample Presentations by Dr. Floyd Taub:

  • Society For Orthomolecular Health-Medicine, 11th Annual Scientific Meeting, About Lyme: Testing, Diagnosis, Therapeutic Protocols, February 27, 2005, San Francisco, California, “Fatigue Reduction Through Changing Cytokine Patterns”.
  • American Academy of Environmental Medicine 39th Annual Meeting, October 28 - 31, 2004, Hilton Head Island, South Carolina. “Taurox SB™ - the First Available NanoDrug™”
  • Fourth World Conference on Nutritional Medicine in San Francisco, California American Association for Chronic Fatigue Syndrome, Sixth Biennial. May 28, 2004,  “Taurox and NanoDrugs™”
  • International College of Integrative Medicine International Congress, September 10–September 14, 2003, St. Louis, MO.  “Beta Alanine Containing NanoDrugs in the Treatment of Fatigue in Patients with Chronic Fatigue Syndrome Cancer, and HCV.”
  • First International Conference on Whole Person Healing, March 28–March 30, 2003, Washington, DC.  “Immunomodulator Taurox SB™ Reduces Fatigue in Patients with Cancer, HCV and Chronic Fatigue Syndrome.”
  • International Research and Clinical Conference, January 31–February 2, 2003, Chantilly, VA. “Therapy with the Cytokine Modulator Is Associated with Decreased Fatigue in Patients with Chronic Fatigue.”

Listing of Scientific Research concerning Taurox

  1. Taurox SB™ -- Molecular Activity, Safety, and Efficacy, Taub, F.E.
  2. Data on Fatigue, Allergies and Hepatitis from Structured Case Histories and Clinical Outcome Trials of Taurox™
  3. Taurox™ Clinical Trials Protocol
  4. In Vitro Cell Culture In Media Containing Beta-Alanyl-Taurine or Carbobenzoxy Beta-Alanyl-Taurine, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 6,323,025 B1, November 27, 2001
  5. In Vitro Cell Culture In Media Containing Beta-Alanyl-Taurine or Carbobenzoxy Beta-Alanyl-Taurine, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 6,096,536, August 1, 2000
  6. The Anticancer Properties of Taurox SB may be Mediated by an Immunostimulatory Mechanism, Dunn, T.M., Wormsley, S., Taub, F.E., and Pontzer, C.H. Abstract presented at the American Society for Pharmacology and Experimental Therapeutics.
  7. The Immunostimulatory Effects of Taurox SB™, Dunn, T. M., Taub, F. E., Pontzer, C H., Department of Cell Biology and Molecular Genetics, University of Maryland, Submitted for publication 2001
  8. Thesis on the Immunostimulatory Effects of Taurox SB™, Dunn, T. M., Department of Pharmacology and Experimental Therapeutics, University of Maryland at Baltimore School of Medicine, 2000
  9. Therapeutic Use of Vitalethine Modulators in Neoplasis, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 5,578,313, November 26, 1996
  10. Therapeutic Use of Vitalethine Modulators in Neoplasia, Knight, G. D., Scanlen, T. J., University of New Mexico, Issued U.S. Patent Number 5,370,868, December 4, 1994
  11. Vitalethine Modulates Erythropoisis and Neoplasia, Knight, G. D., Laubscher, K. H., Fore, M. L., Clark… Scanlen, T. J., Cancer Research, 1994; 54(21): 5623-35

Taurox Monograph and Toxicology Documents Available

  1. Addendum to Toxicology Monograph on Taurox SB, Rice, S. A., April 1, 2002 (Confidential)
  2. Taurox SB Review Of Dr. Susan Rice's Toxicology Monograph And Response To 4 November 2001 MRC Meeting Report Questions, Hood, R. D., March 29, 2002 (Confidential).
  3. Comparison of Toxicity Risks of Five Common Homeopathic Drugs and Taurox SB, Foxman, E. L., October 23, 2001 (Confidential)
  4. Proving Report Taurox SB, Riley, D., Integrative Medicine Institute, 2001 (Confidential)
  5. Toxicology Monograph on Taurox SB, Rice, S. A., September 13, 2001 (Confidential)
  6. Taurox Monograph Submissions, May 2001 and September 2001 (Confidential)

Contact

Floyd Taub M.D.
Chairman, FindCure.Org
fet@FindCure.Org
303 249-9174
Fax: (206) 600-6413
Fitzsimmons Bioscience Center
Colorado Science and Technology Park
12635 E. Montview Blvd. Suite 100G
Aurora, CO 80045.